"Designing Growth Strategies is in our DNA"

Metastatic Castration-Resistant Prostate Cancer Therapeutics Market Size, Share & Industry Analysis, By Drug Class (Androgen Receptor Inhibitors, Microtubule Inhibitors, Gonadotropin Releasing Hormone (GnRH) Agonist, Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist, and Others), By Route of Administration (Oral and Parenteral), By Therapy (Chemotherapy, Hormonal Therapy, Targeted Therapy, and Immunotherapy), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Last Updated: June 02, 2025 | Format: PDF | Report ID: FBI112690

 


To get information on various segments, share your queries with us

ATTRIBUTE

DETAILS

Study Period

2019-2032

Base Year

2024

Estimated Year

2025

Forecast Period

2025-2032

Historical Period

2019-2023

Growth Rate

CAGR of 22.5% from 2025-2032

Unit

Value (USD Billion)

Segmentation

By Drug Class

  • Androgen Receptor Inhibitors
  • Microtubule Inhibitors
  • Gonadotropin Releasing Hormone (GnRH) Agonist
  • Gonadotropin-Releasing Hormone (GnRH) Receptor Antagonist
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Therapy

  • Chemotherapy
  • Hormonal Therapy
  • Targeted therapy
  • Immunotherapy

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores & Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia Pacific (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (  By Drug Class, By Route of Administration, By Therapy, By Distribution Channel, and By Country/Sub-Region)
    • GCC
    • South Africa
    • Rest of Middle East & Africa

 

  • 2019-2032
  • 2024
  • 2019-2023
  • 278
GET A FREE SAMPLE

    man icon
    Mail icon
Consulting Services
    How will you benefit from our consulting services ?